original ) (raw )A Prospective, Open-label Study to Assess the Safety, Tolerability, and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age
fabianne Carlesse
The Pediatric Infectious Disease Journal, 2018
View PDFchevron_right
Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia
josé vazquez
Antimicrobial Agents and Chemotherapy, 2004
View PDFchevron_right
Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia
G. Raponi
Journal of Chemotherapy, 2010
View PDFchevron_right
Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia
Lai-Chu See
Journal of Microbiology, Immunology and Infection, 2014
View PDFchevron_right
Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
JIN WOONG SUH
Mycopathologia, 2020
View PDFchevron_right
A Randomized, Double-Blind Trial of Anidulafungin versus Fluconazole for the Treatment of Esophageal Candidiasis
Christo Van Rensburg
Clinical Infectious Diseases, 2004
View PDFchevron_right
Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial
Mohlim Ong
BMC Infectious Diseases, 2013
View PDFchevron_right
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
josé vazquez
BMC Infectious Diseases, 2014
View PDFchevron_right
Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial
E. Jacqz-aigrain
British Journal of Clinical Pharmacology
View PDFchevron_right
Comparison of anidulafungin’s and fluconazole’s in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis
Laura Najvar
Clinical Microbiology and Infection, 2012
View PDFchevron_right
Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis
Lei Ma
Antimicrobial Agents and Chemotherapy, 2006
View PDFchevron_right
Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
I. Grigoras
Critical Care, 2011
View PDFchevron_right
Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study
Elio Castagnola
BMC Infectious Diseases, 2014
View PDFchevron_right
Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. results from a six-year study (1996–2001)
Mateu Espasa
Diagnostic Microbiology and Infectious Disease, 2003
View PDFchevron_right
Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines
Antonio D'Avolio
Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive, 2014
View PDFchevron_right
A Randomized and Blinded Multicenter Trial of High‐Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects
Jeannette Lee
Clinical Infectious Diseases, 2003
View PDFchevron_right
Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies
J. Fortún
Open Forum Infectious Diseases, 2021
View PDFchevron_right
In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera
Laura Najvar
Antimicrobial Agents and Chemotherapy, 2007
View PDFchevron_right
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
David Facklam
European Journal of Clinical Microbiology & Infectious Diseases, 2006
View PDFchevron_right
The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient
Debra Skaar
Pharmacotherapy
View PDFchevron_right
Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis
Luis Pinto , Carla Odio
The Pediatric Infectious Disease Journal
View PDFchevron_right
Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort
J. Martinez-Montauti
Clinical Microbiology and Infection, 2016
View PDFchevron_right
High-Dose Micafungin in Neonates and Young Infants with Invasive Candidiasis: Results of a Phase 2 Study
Iliana Bersani
Antimicrobial Agents and Chemotherapy, 2021
View PDFchevron_right
ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp
Γεώργιος Πετρίκκος
Clinical Microbiology and Infection, 2012
View PDFchevron_right
Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis
Chin Fen Neoh
Journal of Antimicrobial Chemotherapy, 2011
View PDFchevron_right
Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis
Gabriele Sganga
International Journal of Antimicrobial Agents, 2012
View PDFchevron_right